secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001104659-21-102855
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics appoints Mark Velleca to Board of Directors
----------------------------------------------------------------------

- Appointed Mark Velleca, M.D., Ph.D. as Class I director effective August 9, 2021.
- Determined independent under Nasdaq listing standards; not appointed to any committees initially.
- Will receive standard non-employee director compensation, including initial equity award per company policy.
- Velleca brings over 20 years biotech experience; previously CEO of G1 Therapeutics (led from Series A to FDA approval).
- No transactions with company requiring disclosure; selected per Board recommendation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465921102855/0001104659-21-102855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465921102855/tm2124656d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-102855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer